Imperatorin is a naturally occurring furanocoumarin found in various plants, including Ammi majus, Angelica archangelica, and Ruta graveolens. It exhibits a range of pharmacological activities, including anti-inflammatory, anti-cancer, and anti-microbial properties. The compound's unique structure, with a furan ring fused to a coumarin ring, contributes to its diverse biological effects. Imperatorin has been studied extensively for its potential therapeutic applications, particularly in treating skin conditions, inflammatory disorders, and certain types of cancer. Research efforts focus on elucidating its mechanisms of action, optimizing its delivery, and exploring its safety and efficacy in clinical trials. Imperatorin is also of interest due to its potential to modulate various cellular pathways, including those involved in cell proliferation, apoptosis, and immune responses. While its therapeutic potential is promising, further research is needed to understand its long-term effects and ensure its safe and effective use.'
imperatorin: tumor necrosis factor antagonist; furanocoumarin from West African medicinal plant Clausena anisata; structure in Negwer, 5th ed, #3005 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
imperatorin : A member of the class of psoralens that is psoralen substituted by a prenyloxy group at position 8. Isolated from Angelica dahurica and Angelica koreana, it acts as a acetylcholinesterase inhibitor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Angelica | genus | A plant genus of the family Apiaceae.[MeSH] | Apiaceae | A large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH] |
| Clausena | genus | A plant genus of the family RUTACEAE. Members contain anethole and CARBAZOLES.[MeSH] | Rutaceae | A plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH] |
| Angelica dahurica | species | [no description available] | Apiaceae | A large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 10212 |
| CHEMBL ID | 453805 |
| CHEBI ID | 5885 |
| SCHEMBL ID | 50437 |
| MeSH ID | M0098999 |
| Synonym |
|---|
| 9-[(3-methyl-2-butenyl)oxy]-7h-furo[3,2-g]-1-benzopyran-7-one |
| DIVK1C_006851 |
| SDCCGMLS-0066373.P001 |
| SPECTRUM_000755 |
| ai3-61725 |
| 5-benzofuranacrylic acid, 6-hydroxy-7-((3-methyl-2-butenyl)oxy)-, delta-lactone |
| 6-hydroxy-7-(3-methyl-2-butenyloxy)-5-benzofuranacrylic acid omega-lactone |
| 7h-furo(3,2-g)(1)benzopyran-7-one, 9-((3-methyl-2-butenyl)oxy)- |
| nsc 402949 |
| einecs 207-581-1 |
| 9-((3-methyl-2-butenyl)oxy)-7h-furo(3,2-g)(1)benzopyran-7-one |
| hsdb 3497 |
| 8-isoamylenoxypsoralen |
| ccris 4346 |
| 9-(3-methylbut-2-enyloxy)-7h-furo(3,2-g)chromen-7-one |
| 9-(3-methylbut-2-enyloxy)furo(3,2-g)chromen-7-one |
| OPREA1_407817 |
| ACON1_001117 |
| SPECTRUM5_000244 |
| BSPBIO_001850 |
| inchi=1/c16h14o4/c1-10(2)5-7-19-16-14-12(6-8-18-14)9-11-3-4-13(17)20-15(11)16/h3-6,8-9h,7h2,1-2h |
| 7h-furo[3,2-g][1]benzopyran-7-one, 9-[(3-methyl-2-butenyl)oxy]- |
| 9-[(3-methylbut-2-en-1-yl)oxy]-7h-furo[3,2-g]chromen-7-one |
| 9-(3-methylbut-2-enyloxy)furo[3,2-g]chromen-7-one |
| marmelosin |
| nsc-402949 |
| wln: t c566 do lvotj bo2uy1&1 |
| ammidin |
| 7h-furo[3, 9-[(3-methyl-2-butenyl)oxy]- |
| pentosalen |
| nsc402949 |
| 8-isopentenyloxypsoralene |
| smr000156241 |
| MLS000574838 |
| imperatorin |
| C09269 |
| 482-44-0 |
| 7h-furo[3,2-g][1]benzopyran-7-one, 9-((3-methyl-2-butenyl)oxy)- |
| 9-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one |
| NCGC00095209-02 |
| NCGC00095209-01 |
| KBIOSS_001235 |
| KBIO3_001050 |
| KBIO2_003803 |
| KBIO2_001235 |
| KBIO2_006371 |
| KBIOGR_001864 |
| KBIO1_001795 |
| SPECTRUM4_001422 |
| SPECTRUM2_000376 |
| SPBIO_000531 |
| SPECPLUS_000755 |
| SPECTRUM3_000145 |
| SPECTRUM102076 |
| MEGXP0_000089 |
| NCGC00169661-01 |
| NCGC00169661-02 |
| NCGC00095209-05 |
| AKOS000277029 |
| CHEMBL453805 , |
| chebi:5885 , |
| HMS1922N22 |
| (9-[(3-methyl-2-buten-1-yl)oxy]-7h-furo[3,2-g][1]benzopyran-7-one) |
| bdbm50308719 |
| NCGC00095209-04 |
| NCGC00095209-03 |
| HMS3261C08 |
| tox21_113179 |
| dtxcid5028663 |
| dtxsid8048737 , |
| cas-482-44-0 |
| A827504 |
| 9-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one;imperatorin |
| HMS2218G08 |
| S3809 |
| CCG-38649 |
| unii-k713n25c78 |
| pentosalen [ban] |
| k713n25c78 , |
| marmelide |
| 9-[(3-methyl-2-buten-1-yl)oxy]-7h-furo[3,2-g][1]benzopyran-7-one |
| FT-0603414 |
| LP00413 |
| marmelosin [usp-rs] |
| imperatorin [mi] |
| 6-hydroxy-7-(3-methyl-2-butenyloxy)-5-benzofuranacrylic acid .gamma.-lactone |
| pentosalen [hsdb] |
| pentosalen [who-dd] |
| HMS3354E04 |
| SCHEMBL50437 |
| tox21_113179_1 |
| NCGC00095209-06 |
| tox21_500413 |
| NCGC00261098-01 |
| 9-[(3-methylbut-2-enyl)oxy]-7h-furo[3,2-g][1]benzopyran-7-one |
| 5-benzofuranacrylic acid, 6-hydroxy-7-((3-methyl-2-butenyl)oxy)-, .delta.-lactone |
| 9-[(3-methyl-2-butenyl)oxy]-7h-furo[3,2-g]chromen-7-one # |
| 7h-furo[3,2-g][1]benzopyran-7-one, 9-[(3-methyl-2-buten-1-yl)oxy]- |
| Q-100532 |
| 9-((3-methylbut-2-en-1-yl)oxy)-7h-furo[3,2-g]chromen-7-one |
| mfcd00016881 |
| 9-[(3-methylbut-2-en-1-yl)oxy]-2h-furo[3,2-g]chromen-2-one |
| 9-(3-methylbut-2-enyloxy)-7h-furo[3,2-g]chromen-7-one |
| AC-8046 |
| SR-01000721772-2 |
| sr-01000721772 |
| marmelosin, analytical standard |
| imperatorin, >=98% (hplc), powder |
| AS-71539 |
| marmelosin (usp-rs) |
| 6-hydroxy-7-(3-methyl-2butenyloxy)-5-benzofuranacrylic acid delta-lactone |
| 9-((3-methyl-2-butenyl)oxy)-7h-furo(3,2-g)-1-benzopyran-7-one |
| 9-((3-methylbut-2-en-1-yl)oxy)-7h-furo(3,2-g)chromen-7-one |
| 6-hydroxy-7-(3-methyl-2-butenyloxy)-5-benzofuranacrylic acid gamma-lactone |
| imperatorin, european pharmacopoeia (ep) reference standard |
| 9-(3-methyl-2-butenyloxy)-7-oxofuro[3,2-g]chromene |
| 9-[(3-methyl-2-butenyl)oxy]-7h-furo[3,2-g][1]benzopyran-7-one, 9ci |
| pentasalen, ban |
| CS-5800 |
| HY-N0285 |
| 9-[(3-methyl-2-buten-1-yl)oxy]-7h-furo[3,2-g]chromen-7-one |
| 9-(3-methyl-but-2-enyloxy)-furo[3,2-g]chromen-7-one |
| 9-(3-methylbut-2-enyloxy)-7h-furo |
| [3,2-g]chromen-7-one |
| imperatorin,(s) |
| 8-prenyloxypsoralen |
| I0904 |
| 8-(3-methyl-2-butenyloxy)psoralen |
| BCP28280 |
| Q1649534 |
| A14565 |
| SDCCGSBI-0052715.P002 |
| NCGC00095209-12 |
| HMS3885G06 |
Imperatorin (IMP) is a furanocoumarin derivative and an effective ingredient in several Chinese medicinal herbs. It is a secondary metabolite of plants and is most abundant in Angelica dahurica.
Imperatorin (IMP) has been reported to alleviate mast cell-mediated allergic responses by suppressing the expression of Nrf-2, ARE, and HO-1.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Imperatorin has a mitigating effect on detrusor overactivity." | ( The Assessment of the Efficacy of Imperatorin in Reducing Overactive Bladder Symptoms. Bojar, I; Dobrowolski, P; Iwaniak, P; Jakimiuk, A; Kluz, T; Misiek, M; Poleszak, E; Stangel-Wójcikiewicz, K; Wdowiak, A; Wróbel, A; Wróbel, J; Zapała, Ł, 2023) | 1.91 |
| "Imperatorin has a mitigating effect on detrusor overactivity." | ( The Assessment of the Efficacy of Imperatorin in Reducing Overactive Bladder Symptoms. Bojar, I; Dobrowolski, P; Iwaniak, P; Jakimiuk, A; Kluz, T; Misiek, M; Poleszak, E; Stangel-Wójcikiewicz, K; Wdowiak, A; Wróbel, A; Wróbel, J; Zapała, Ł, 2023) | 1.91 |
| "Imperatorin (IMP) has been reported to alleviate mast cell-mediated allergic responses by suppressing the expression of Nrf-2, ARE, and HO-1." | ( Imperatorin Relieved Ulcerative Colitis by Regulating the Nrf-2/ARE/HO-1 Pathway in Rats. Luo, M; Luo, Y, 2021) | 2.79 |
Imperatorin didn't inhibit SOCE-mediated increases in cytosolic Ca(2+) levels evoked by the emptying of the stores. At lower doses of 20 and 30 mg/kg had no significant effect on the anticonvulsant activities of conventional antiepileptic drugs.
Imperatorin treatment decreased vascular superoxide anion production and downregulated aortic NADPH oxidase subunit p47. Pretreatment with Imperatorin (15 or 30 mg/kg) decreased lung wet-to-dry weight (W/D) ratio, the number of inflammatory cells and myeloperoxidase (MPO) activities.
The aim of this study was to determine and compare the anticonvulsant and acute adverse (neurotoxic) effects of imperatorin and osthole with valproate (a classical antiepileptic drug) in the maximal electroshock seizure and chimney tests in mice.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The aim of this study was to determine and compare the anticonvulsant and acute adverse (neurotoxic) effects of imperatorin and osthole (two natural coumarin derivatives) with valproate (a classical antiepileptic drug) in the maximal electroshock seizure and chimney tests in mice." | ( Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Andres-Mach, M; Cisowski, W; Czuczwar, SJ; Glensk, M; Glowniak, K; Luszczki, JJ; Wojda, E, 2009) | 0.82 |
| " Based on the above defects, we believe that more in vivo experiments of imperatorin should be carried out in the future; future research need to explore synergistic mechanisms of imperatorin with other drugs, especially in anticancer; the dose affects both the pharmacological activity and the side effect of imperatorin." | ( Imperatorin: A review of its pharmacology, toxicity and pharmacokinetics. Deng, M; Li, X; Liao, Y; Liu, L; Xie, L; Zhong, L, 2020) | 2.23 |
The phamacokinetic parameters AUC and Cmax were significantly increased. The coumarin constituents in Angelica dahurica could promote the oral bioavailability of docetaxel.
Coumarin constituents in Angelica dahurica could promote the oral bioavailability of docetaxel. The effects were in the following order: oxypeucedanin> isoimperatorin> imperatorin.
| Excerpt | Reference | Relevance |
|---|---|---|
| " IMP sustained-release tablets exhibited a more sustained plasma concentration than the plain tablets, with a relative bioavailability of 127." | ( Imperatorin sustained-release tablets: In vitro and pharmacokinetic studies. He, L; Li, C; Lu, W; Pan, J; Wang, S, 2010) | 1.8 |
| "In this study, a simple and sensitive gas chromatography-mass spectrometry method was developed for the study of bioavailability and protein binding and the metabolism of imperatorin in rat." | ( Simultaneous determination of imperatorin and its metabolites in vitro and in vivo by a GC-MS method: application to a bioavailability and protein binding ability study in rat plasma. Du, W; Peng, C; Wang, S; Zhao, G, 2014) | 0.89 |
| " The phamacokinetic parameters AUC and Cmax were significantly increased, indicating that coumarin constituents in Angelica dahurica could promote the oral bioavailability of docetaxel, and their effects were in the following order: oxypeucedanin> isoimperatorin> imperatorin." | ( [Effect investigation of coumarin constituents in Angelica dahurica on pharmacokinetics of docetaxel by LC-MS]. Dong, W; Guan, XJ; Guan, YM; Liang, XL; Liao, ZG; Zhao, GW; Zhu, WF, 2017) | 0.64 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The evaluation of time-course and dose-response relationships for imperatorin, osthole and valproate in the maximal electroshock seizure test revealed that the compounds produced a clear-cut antielectroshock action in mice and the experimentally derived ED(50) values for imperatorin ranged between 167 and 290 mg/kg, those for osthole ranged from 253 to 639 mg/kg, whereas the ED(50) values for valproate ranged from 189 to 255 mg/kg." | ( Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Andres-Mach, M; Cisowski, W; Czuczwar, SJ; Glensk, M; Glowniak, K; Luszczki, JJ; Wojda, E, 2009) | 0.85 |
| " dosage highly unlikely to have an effect on nocturia or any other pharmacologically significant effect in humans." | ( Investigations on the constituents of SagaPro tablets, a food supplement manufactured from Eyjolfsson, R; Kowal, NM; Olafsdottir, ES, 2017) | 0.46 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| EC 3.1.1.7 (acetylcholinesterase) inhibitor | An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| psoralens | A furanocoumarin with a 7H-furo[3,2-g]chromen-7-one skeleton and its substituted derivatives thereof. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.0282 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 16.7761 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 17.7828 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 2.2387 | 0.0184 | 6.8060 | 14.1254 | AID624172 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 56.2341 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| GLS protein | Homo sapiens (human) | Potency | 19.9526 | 0.3548 | 7.9355 | 39.8107 | AID624146 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 8.4127 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 22.4209 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 11.6074 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 16.7855 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 79.4328 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| isocitrate dehydrogenase 1, partial | Homo sapiens (human) | Potency | 15.8489 | 6.3096 | 27.0990 | 79.4328 | AID602179 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 16.2322 | 0.0015 | 30.6073 | 15,848.9004 | AID1224819; AID1224820; AID1224821 |
| G | Vesicular stomatitis virus | Potency | 0.3467 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 0.8709 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 33.5875 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 6.0852 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 0.4772 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 28.1838 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2242 |
| hexokinase-4 isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 2.5119 | 13.8003 | 28.1838 | AID743205 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 89.1251 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID488953 |
| glucokinase regulatory protein | Homo sapiens (human) | Potency | 22.3872 | 2.5119 | 13.8003 | 28.1838 | AID743205 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.6795 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 100.0000 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 21.1300 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 5.0119 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Interferon beta | Homo sapiens (human) | Potency | 0.3467 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 0.3467 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 28.1838 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 28.1838 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 3.9811 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 0.3467 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 0.3467 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 0.7569 | 0.0601 | 10.7453 | 37.9330 | AID485368 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 4.0000 | 5.9750 | 8.5000 | AID630399 |
| Beta-secretase 1 | Homo sapiens (human) | IC50 (µMol) | 61.1500 | 0.0006 | 1.6194 | 10.0000 | AID456256; AID637774 |
| Cytochrome P450 1B1 | Homo sapiens (human) | Ki | 1.0000 | 0.0030 | 0.9741 | 7.4600 | AID1452999 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1355969 | Cytotoxicity against human MDA-MB-231 cells by MTT assay | 2018 | Journal of natural products, 07-27, Volume: 81, Issue:7 | Bioactive Phenolic Components from the Twigs of Atalantia buxifolia. |
| AID1256912 | Inhibition of human IDH1 R132H mutant expressed in IPTG-induced Escherichia coli BL21 cells assessed as oxidation of NADPH to NADP+ after 5 mins by spectrophotometry | 2015 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23 | Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1. |
| AID402906 | Antiviral activity against hepatitis B virus infected in human MS-G2 cells assessed as inhibition of e-antigen production at 100 uM after 48 hrs | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | Biotransformation of imperatorin by Aspergillus flavus. |
| AID1639406 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced nitrite production at 1.5 to 15 ug/ml preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by Griess assay | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1355972 | Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release preincubated for 5 mins followed by fMLP/CB stimulation and measured for 10 mins using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate | 2018 | Journal of natural products, 07-27, Volume: 81, Issue:7 | Bioactive Phenolic Components from the Twigs of Atalantia buxifolia. |
| AID456256 | Inhibition of human recombinant BACE1 after 60 mins by fluorescence assay | 2010 | Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1 | Biotransformation of isoimperatorin and imperatorin by Glomerella cingulata and beta-secretase inhibitory activity. |
| AID637774 | Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate after 60 mins by fluorescence quenching assay | 2012 | Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2 | Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor. |
| AID402910 | Cytotoxicity against human MS-G2 cells at 50 uM by MTT assay | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | Biotransformation of imperatorin by Aspergillus flavus. |
| AID1639398 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced iNOS protein expression preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by Western blotting analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639427 | Effect on IKK phosphorylation in mouse MHS cells assessed as phosphorylated IKK level at 15 ug/ml by Western blot analysis relative to tubulin (Rvb = 1 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID400910 | Induction of DNA fragmentation at G1/S phase in human Jurkat cells after 72 hrs by propidium iodide and FITC-dUTP double staining | 2004 | Journal of natural products, Apr, Volume: 67, Issue:4 | Coumarins from Opopanax chironium. New dihydrofuranocoumarins and differential induction of apoptosis by imperatorin and heraclenin. |
| AID1639412 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced IL-6 mRNA expression preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by TRIzol reagent based qRT-PCR analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID452743 | Inhibition of Escherichia coli MG1655 enoyl-ACP reductase overexpressed in Escherichia coli M15 assessed as oxidation of NADH to NAD+ at 5 uM after 5 mins | 2010 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1 | Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers. |
| AID1639424 | Inhibition of zymosan-induced IKK phosphorylation in mouse MHS cells by Western blot analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID334656 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction | |||
| AID1639392 | Antiinflammatory activity in zymosan induced C57BL/6 mouse model of lung injury assessed as reduction in wet to dry lung edema ratio at 4 mg/kg, ip pretreated for 3 days followed by zymosan challenge and measured after 24 hrs | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639395 | Antiinflammatory activity in zymosan induced C57BL/6 mouse model of lung injury assessed as reduction in immune cell infiltration in BALF at 4 mg/kg, ip pretreated for 3 days followed by zymosan challenge and measured after 24 hrs by Diff-Quick staining b | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1271450 | Vasodilator activity in Sprague-Dawley rat mesentric artery assessed as reduction in of K+-induced contraction relative to control | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Synthesis and fluorescent study of 5-phenyl furocoumarin derivatives as vasodilatory agents. |
| AID1639419 | Inhibition of zymosan-induced JAK1 phosphorylation in mouse MHS cells assessed as phosphorylated JAK1 level at 15 ug/ml by Western blot analysis relative to tubulin (Rvb = 2.2 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639414 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced IL-6 protein expression at 1.5 to 15 ug/ml preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639393 | Antiinflammatory activity in zymosan induced C57BL/6 mouse model of lung injury assessed as reduction in total protein level in BALF at 4 mg/kg, ip pretreated for 3 days followed by zymosan challenge and measured after 24 hrs | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1359333 | Induction of melanogenesis in mouse Melan-a cells assessed as effect on tanning property at 40 uM after 48 hrs | 2018 | European journal of medicinal chemistry, May-25, Volume: 152 | Natural oxyprenylated coumarins are modulators of melanogenesis. |
| AID630399 | Inhibition of GST-tagged human VHR using pNpp as substrate after 30 mins | 2011 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22 | Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2. |
| AID334652 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction | |||
| AID1639422 | Effect on JAK1 phosphorylation in mouse MHS cells assessed as phosphorylated JAK1 level at 15 ug/ml by Western blot analysis relative to tubulin (Rvb = 1 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639405 | Effect on COX2 protein expression in mouse MHS cells at 15 ug/ml after 30 mins by Western blotting analysis relative to tubulin (Rvb = 1 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639402 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced COX2 protein expression at 1.5 ug/ml preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by Western blotting analysis relative to contr | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639400 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced iNOS protein expression at 1.5 ug/ml preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by Western blotting analysis relative to contr | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639425 | Inhibition of zymosan-induced IKK phosphorylation in mouse MHS cells assessed as phosphorylated IKK level at 1.5 ug/ml by Western blot analysis relative to tubulin (Rvb = 1.8 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1271449 | Vasodilator activity in Sprague-Dawley rat mesentric artery assessed as reduction in of K+-induced contraction | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Synthesis and fluorescent study of 5-phenyl furocoumarin derivatives as vasodilatory agents. |
| AID1639408 | Effect on nitrite level in mouse MHS cells at 1.5 to 15 ug/ml after 30 mins by Griess assay | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID334653 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction | |||
| AID402631 | Antiviral activity against hepatitis B virus infected in human MS-G2 cells assessed as inhibition of surface antigen production at 50 uM after 48 hrs | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | Biotransformation of imperatorin by Aspergillus flavus. |
| AID334660 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 600 ug/plate after 72 hrs | |||
| AID1639426 | Inhibition of zymosan-induced IKK phosphorylation in mouse MHS cells assessed as phosphorylated IKK level at 15 ug/ml by Western blot analysis relative to tubulin (Rvb = 1.8 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1359334 | Inhibition of melanogenesis in mouse Melan-a cells assessed as effect on whitening property at 40 uM after 48 hrs | 2018 | European journal of medicinal chemistry, May-25, Volume: 152 | Natural oxyprenylated coumarins are modulators of melanogenesis. |
| AID334658 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction | |||
| AID402907 | Antiviral activity against hepatitis B virus infected in human MS-G2 cells assessed as inhibition of e-antigen production at 50 uM after 48 hrs | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | Biotransformation of imperatorin by Aspergillus flavus. |
| AID1639404 | Effect on iNOS protein expression in mouse MHS cells at 15 ug/ml after 30 mins by Western blotting analysis relative to tubulin (Rvb = 1 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID334657 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction | |||
| AID1639390 | Antiinflammatory activity in zymosan induced C57BL/6 mouse model of lung injury assessed as reduction in subepithelial collagen deposition/fibrosis at 4 mg/kg, ip pretreated for 3 days followed by zymosan challenge and measured after 24 hrs by Masson's tr | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1327079 | Neuroprotective activity in human SH-SY5Y cells assessed as reduction in oxygen glucose deprivation-induced cell death incubated for 16 hrs under hypoxic condition followed by incubation for 24 hrs under normoxic condition by MTT assay | 2016 | Journal of natural products, 08-26, Volume: 79, Issue:8 | Chemical Constituents Isolated from the Root Bark of Cudrania tricuspidata and Their Potential Neuroprotective Effects. |
| AID1639411 | Cytotoxicity against zymosan-induced mouse MHS cells assessed as effect on cell viability at 1.5 to 15 ug/ml preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by sulforhodamine B assay | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639409 | Effect on PGE2 level in mouse MHS cells at 1.5 to 15 ug/ml after 30 mins by Griess assay | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639413 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced TNFalpha mRNA expression preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by TRIzol reagent based qRT-PCR analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639420 | Inhibition of zymosan-induced STAT3 phosphorylation in mouse MHS cells assessed as phosphorylated STAT3 level at 1.5 ug/ml by Western blot analysis relative to tubulin (Rvb = 2.1 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639417 | Inhibition of zymosan-induced STAT3 phosphorylation in mouse MHS cells preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by Western blot analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1151356 | Antiinflammatory activity in human neutrophil assessed as inhibition of FMLP/CB-induced elastase release for 5 mins | 2014 | Journal of natural products, May-23, Volume: 77, Issue:5 | Constituents of the roots of Clausena lansium and their potential anti-inflammatory activity. |
| AID671764 | Inhibition of HCV NS3 helicase ATP hydrolysis activity overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of inorganic phosphate release by AM/MG-based colometric analysis in the presence of M13 ssDNA | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. |
| AID1256913 | Inhibition of human IDH1 expressed in IPTG-induced Escherichia coli BL21 cells assessed as reduction of NADP+ to NADPH after 5 mins by spectrophotometry | 2015 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23 | Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1. |
| AID1411730 | Inhibition of recombinant human CYP1A1 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 7-ethoxyresorufin substrate by EROD assay relative to control | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy |
| AID380793 | Displacement of [3H]LSD from human recombinant 5HT7 receptor expressed in CHO cells at 100 uM by liquid scintillation counting relative to control | 2006 | Journal of natural products, Apr, Volume: 69, Issue:4 | Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. |
| AID1355970 | Cytotoxicity against human A549 cells by MTT assay | 2018 | Journal of natural products, 07-27, Volume: 81, Issue:7 | Bioactive Phenolic Components from the Twigs of Atalantia buxifolia. |
| AID334650 | Toxicity in Salmonella Typhimurium T98 at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction | |||
| AID400908 | Induction of cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase at 25 ug/mL after 48 hrs | 2004 | Journal of natural products, Apr, Volume: 67, Issue:4 | Coumarins from Opopanax chironium. New dihydrofuranocoumarins and differential induction of apoptosis by imperatorin and heraclenin. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1151355 | Antiinflammatory activity in human neutrophil assessed as inhibition of FMLP/CB-induced superoxide anion generation pretreated for 5 mins by spectrophotometry | 2014 | Journal of natural products, May-23, Volume: 77, Issue:5 | Constituents of the roots of Clausena lansium and their potential anti-inflammatory activity. |
| AID1639421 | Inhibition of zymosan-induced STAT3 phosphorylation in mouse MHS cells assessed as phosphorylated STAT3 level at 15 ug/ml by Western blot analysis relative to tubulin (Rvb = 2.1 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID334662 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 150 ug/plate after 72 hrs | |||
| AID1357280 | Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation | 2018 | European journal of medicinal chemistry, Jun-10, Volume: 153 | Recent acquisitions on oxyprenylated secondary metabolites as anti-inflammatory agents. |
| AID671761 | Inhibition of SARS coronavirus nsP13 helicase activity expressed in Escherichia coli Rosetta assessed inhibition of DNA unwinding activity at 10 uM by FRET assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. |
| AID334655 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction | |||
| AID402909 | Cytotoxicity against human MS-G2 cells at 100 uM by MTT assay | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | Biotransformation of imperatorin by Aspergillus flavus. |
| AID1615747 | Hepatoprotective activity against H2O2-induced cell death in human HepG2 cells assessed as cell viability at 10 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 24 hrs by EZ-Cytox cell viability assay (Rvb = 43.9 +/- 5.25%) | 2019 | Journal of natural products, 09-27, Volume: 82, Issue:9 | Furanocoumarins from the Roots of |
| AID666151 | Inhibition of PA endonuclease at 1 uM | 2011 | PloS one, , Volume: 6, Issue:5 | Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts. |
| AID1639387 | Antiinflammatory activity in zymosan induced C57BL/6 mouse model of lung injury assessed as reduction in immune cell infiltration at 4 mg/kg, ip pretreated for 3 days followed by zymosan challenge and measured after 24 hrs by H and E staining based micros | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1357277 | Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS gene expression relative to control | 2018 | European journal of medicinal chemistry, Jun-10, Volume: 153 | Recent acquisitions on oxyprenylated secondary metabolites as anti-inflammatory agents. |
| AID1357278 | Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced COX-2 gene expression relative to control | 2018 | European journal of medicinal chemistry, Jun-10, Volume: 153 | Recent acquisitions on oxyprenylated secondary metabolites as anti-inflammatory agents. |
| AID1551064 | Positive allosteric modulation of human GABA-A alpha1beta2gamma2S receptor expressed in Xenopus laevis oocytes assessed as increase in GABA-induced chloride channel current at 100 uM by two-electrode voltage clamp method relative to control | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators. |
| AID402905 | Antiviral activity against hepatitis B virus infected in human MS-G2 cells assessed as inhibition of surface antigen production at 10 uM after 48 hrs | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | Biotransformation of imperatorin by Aspergillus flavus. |
| AID1639399 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced COX2 protein expression preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by Western blotting analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID400906 | Induction of cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 48 hrs | 2004 | Journal of natural products, Apr, Volume: 67, Issue:4 | Coumarins from Opopanax chironium. New dihydrofuranocoumarins and differential induction of apoptosis by imperatorin and heraclenin. |
| AID1639401 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced iNOS protein expression at 15 ug/ml preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by Western blotting analysis relative to contro | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID334659 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction | |||
| AID1639403 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced COX2 protein expression at 15 ug/ml preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by Western blotting analysis relative to contro | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1327078 | Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 1-methyl-4-phenylpyridinium ion-induced cell death after 48 hrs by MTT assay | 2016 | Journal of natural products, 08-26, Volume: 79, Issue:8 | Chemical Constituents Isolated from the Root Bark of Cudrania tricuspidata and Their Potential Neuroprotective Effects. |
| AID1359332 | Cytotoxicity against mouse Melan-a cells assessed as effect on cell viability at <2 uM after 24 to 72 hrs by trypan blue exclusion assay | 2018 | European journal of medicinal chemistry, May-25, Volume: 152 | Natural oxyprenylated coumarins are modulators of melanogenesis. |
| AID1639394 | Antiinflammatory activity in zymosan induced C57BL/6 mouse model of lung injury assessed as reduction in PGE2 production in BALF at 4 mg/kg, ip pretreated for 3 days followed by zymosan challenge and measured after 24 hrs by ELISA | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639423 | Effect on STAT3 phosphorylation in mouse MHS cells assessed as phosphorylated STAT3 level at 15 ug/ml by Western blot analysis relative to tubulin (Rvb = 1 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1452999 | Competitive inhibition of CYP1B1 (unknown origin) expressed in yeast microsomes using (-)benzo[a]pyrene-7R-trans-7,8-dihyrodiol (B[a]P-7,8-diol) as substrate | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Inhibitors of cytochrome P450 (CYP) 1B1. |
| AID402630 | Antiviral activity against hepatitis B virus infected in human MS-G2 cells assessed as inhibition of surface antigen production at 100 uM after 48 hrs | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | Biotransformation of imperatorin by Aspergillus flavus. |
| AID334651 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction | |||
| AID334661 | Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 300 ug/plate after 72 hrs | |||
| AID611884 | Antiproliferative activity against serum-stimulated primary rat aortic VSMC at 30 uM after 30 mins by resazurin conversion assay | 2011 | Journal of natural products, Jun-24, Volume: 74, Issue:6 | Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation. |
| AID1639418 | Inhibition of zymosan-induced JAK1 phosphorylation in mouse MHS cells assessed as phosphorylated JAK1 level at 1.5 ug/ml by Western blot analysis relative to tubulin (Rvb = 2.2 No_unit) | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639416 | Inhibition of zymosan-induced JAK1 phosphorylation in mouse MHS cells preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by Western blot analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639407 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced PGE2 production at 1.5 to 15 ug/ml preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by ELISA | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1355971 | Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation preincubated for 5 mins followed by cytochalasin B/fMLP addition for 3 mins by superoxide dismutase inhibitable reduction of ferricytochro | 2018 | Journal of natural products, 07-27, Volume: 81, Issue:7 | Bioactive Phenolic Components from the Twigs of Atalantia buxifolia. |
| AID1639428 | Inhibition of zymosan-induced NFkappaB p65 nuclear translocation in mouse MHS cells at 15 ug/ml by DAPI staining based immunofluorescence microscopic analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID671762 | Inhibition of HCV NS3 helicase overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of DNA unwinding activity at 10 uM by FRET assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. |
| AID1639389 | Antiinflammatory activity in zymosan induced C57BL/6 mouse model of lung injury assessed as reduction in thinkened basement membrane at 4 mg/kg, ip pretreated for 3 days followed by zymosan challenge and measured after 24 hrs by H and E staining based mic | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1615746 | Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM incubated for 1 hr by EZ-Cytox cell viability assay | 2019 | Journal of natural products, 09-27, Volume: 82, Issue:9 | Furanocoumarins from the Roots of |
| AID402911 | Cytotoxicity against human MS-G2 cells at 10 uM by MTT assay | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | Biotransformation of imperatorin by Aspergillus flavus. |
| AID1639410 | Cytotoxicity against mouse MHS cells assessed as effect on cell viability at 1.5 to 15 ug/ml measured after 30 mins by sulforhodamine B assay | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1357279 | Anti-inflammatory activity in mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg preincubated for 5 hrs followed by carrageenan challenge relative to control | 2018 | European journal of medicinal chemistry, Jun-10, Volume: 153 | Recent acquisitions on oxyprenylated secondary metabolites as anti-inflammatory agents. |
| AID1639391 | Antiinflammatory activity in zymosan induced C57BL/6 mouse model of lung injury assessed as reduction in collagen deposition at 4 mg/kg, ip pretreated for 3 days followed by zymosan challenge and measured after 24 hrs by hydroxyproline assay | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1639397 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced COX2 mRNA expression preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by TRIzol reagent based qRT-PCR analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639396 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced iNOS mRNA expression preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs by TRIzol reagent based qRT-PCR analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1615748 | Inhibition of H2O2-induced ROS accumulation in human HepG2 cells assessed as ROS generation at 10 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 30 mins by H2DCFDA staining based flow cytometry (Rvb = 100 +/- 11.53%) | 2019 | Journal of natural products, 09-27, Volume: 82, Issue:9 | Furanocoumarins from the Roots of |
| AID630398 | Inhibition of GST-tagged human SHP2 N-terminal SH2 domain deficient mutant PTP activity using pNpp as substrate after 30 mins | 2011 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22 | Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2. |
| AID1639386 | Effect on morphological changes in lungs of C57BL/6 mouse at 4 mg/kg, ip administered for 3 days by H and E staining based microscopic analysis | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID402908 | Antiviral activity against hepatitis B virus infected in human MS-G2 cells assessed as inhibition of e-antigen production at 10 uM after 48 hrs | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | Biotransformation of imperatorin by Aspergillus flavus. |
| AID630402 | Inhibition of GST-tagged human HePTP using pNpp as substrate after 30 mins | 2011 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22 | Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2. |
| AID666150 | Inhibition of PA endonuclease at 10 uM | 2011 | PloS one, , Volume: 6, Issue:5 | Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts. |
| AID1355968 | Cytotoxicity against human HepG2 cells by MTT assay | 2018 | Journal of natural products, 07-27, Volume: 81, Issue:7 | Bioactive Phenolic Components from the Twigs of Atalantia buxifolia. |
| AID1639415 | Antiinflammatory activity in mouse MHS cells assessed as reduction in zymosan-induced TNFalpha protein expression at 1.5 to 15 ug/ml preincubated for 30 mins followed by zymosan challenge and measured after 6 to 24 hrs | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID1639388 | Antiinflammatory activity in zymosan induced C57BL/6 mouse model of lung injury assessed as reduction in hypertrophic smooth muscle cells at 4 mg/kg, ip pretreated for 3 days followed by zymosan challenge and measured after 24 hrs by H and E staining base | 2019 | Journal of natural products, 04-26, Volume: 82, Issue:4 | Anti-inflammatory Property of Imperatorin on Alveolar Macrophages and Inflammatory Lung Injury. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 10 (3.89) | 18.7374 |
| 1990's | 10 (3.89) | 18.2507 |
| 2000's | 55 (21.40) | 29.6817 |
| 2010's | 136 (52.92) | 24.3611 |
| 2020's | 46 (17.90) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (36.58) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 9 (3.35%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 260 (96.65%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||